



Silva Pharmaceuticals Limited

সিলভা ফার্মাসিউটিক্যালস লিমিটেড

Ref: SPL/SD/2025/129
Date: October 28, 2025



- The Chairman
Bangladesh Securities and Exchange Commission (BSEC),
Dhaka-1207
- Managing Director
Dhaka Stock Exchange PLC (DSE),
Dhaka-1000
- Managing Director
Chittagong Stock Exchange PLC (CSE),
Chittagong

Subject: Board of Directors Meeting regarding Price Sensitive Information for Annual Financial Statements for the year ended 30th June, 2025 of Silva Pharmaceuticals Limited.

Dear Sir,
We are pleased to inform you that the Board of Directors Meeting of Silva Pharmaceuticals Limited held on Tuesday, 28th October, 2025 during 3.30 P.M. to 4.30 P.M. at its Corporate Office: House No. # 65, Road No. # 8/A, Dhanmondi, Dhaka-1209 and approved the Annual Financial Statements of the Company for the year ended 30th June, 2025 and took the following decisions in respect of holding 24th Annual General Meeting (AGM):

- Recommended Dividend : No Dividend.
- Date and Time of AGM : Tuesday, December 30, 2025 at 11:30 A.M.
- Venue of AGM : Hybrid System(Both physical & Digital Platform)
- Record Date : Monday, December 01, 2025

The comparative key financial disclosures as per audited financial statements:

SL.NO.	Particulars	30-June-2025	30-June-2024
A.	Net Asset Value (NAV)	Tk. 2,113,040,947	Tk. 2,255,949,495
B.	Net Asset Value Per Share(NAVPS)*	Tk.15.48	Tk.16.53
		01-July-2024 to 30-June-2025	01-July-2023 to 30-June-2024
C.	Net Profit after tax	Tk. (132,951,398)	Tk. (64,484,814)
D.	Earnings per Share (EPS) *	Tk. (0.97)	Tk. (0.47)
E.	Net Operating Cash Flow per Share (NOCFPS)	Tk. 0.10	Tk. 0.03

* Reason for increase/decrease in the Financial Results: The decline in net profit after tax compared to the previous year was primarily due to a significant reduction in sales volume, resulting from supply chain disruptions caused by the ongoing dollar crisis and substantial movement of sales personnel. Additionally, external challenges such as flash floods in key business regions, political unrest, and global macroeconomic instability, further adversely affected the company's overall performance. The lower Earnings per Share (EPS) were mainly attributable to decreased revenue and increased operating expenses. Consequently, the net loss incurred during the financial year led to a corresponding decline in the Net Asset Value per Share (NAVPS).

This is for your kind information and record.

Thanking you.

Sincerely,

Md. Javed Hossain
Company Secretary

